Qlife leaves development programme at Herlev Hospital
Qlife has been part of a development programme at the oncology department at Herlev Hospital since 2018, intended to validate home monitoring of kidney cancer patients. The project has been delayed several times and has been on hold since the pandemic outbreak early 2020. Qlife was to deliver Egoo devices, data integration and biomarker tests of CRP, Hb, ALAT and Sutent. The biomarker for CRP and Hb was delivered early 2020. Upon the outbreak of Corona virus and the temporary hold of the development programme, Qlife made a change in the short-term strategy, and followed the path of